Bevacizumab (Avastin)

Immunotherapy · Approved since 2004

US FDA Approved EU EMA Approved ES Funded by SNS approved in CRC IV 512 Clinical Trials
VEGF-A

Description

Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) and serves as a cornerstone anti-angiogenic therapy in colorectal cancer treatment. It is approved for first-line treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy regimens such as FOLFOX or FOLFIRI. The drug is used across different molecular subtypes of CRC including microsatellite stable (MSS) and microsatellite instability-high (MSI-H) tumors, and regardless of KRAS, NRAS, or BRAF mutation status. Bevacizumab is also employed in second-line metastatic settings and is being combined with newer immunotherapy agents in pMMR/MSS colorectal cancer.

Mechanism of Action

Bevacizumab es un anticuerpo monoclonal anti-VEGF-A que inhibe la angiogenesis tumoral, normalizando la vasculatura y mejorando la entrega de quimioterapia.

Molecular Targets

Side Effects

Hypertension Proteinuria Bleeding/hemorrhage Delayed wound healing Arterial thromboembolic events Gastrointestinal perforation Fatigue Diarrhea

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07525206 Phase 3
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cance
United States, Belgium, Greece, Japan, Portugal, South Korea, Spain, Taiwan
NCT07500298 Phase 1
Recruiting
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
United States
NCT07549399 Phase 3
Recruiting
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
China
NCT07527858 Phase 2
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
United States, Australia, South Korea, Spain
NCT07549412 Phase 3
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
United States, Australia, Canada, Japan, South Korea, Taiwan
NCT07446322 Phase 2
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
United States
View all 512 clinical trials →

Quick Info

Brand NameAvastin
CategoryImmunotherapy
US StatusFDA Approved
EU EMA StatusEMA Approved
ES Spain AccessFunded by SNS approved in CRC
AdministrationIV
Year Approved2004
Clinical Trials512
View Clinical Trials Back to Drug Glossary

Regimens with this Drug

FOLFOX + Bev
Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab
1st line
FOLFIRI + Bev
Fluorouracil + Leucovorin + Irinotecan + Bevacizumab
1st line, 2nd line
FOLFOXIRI + Bev
Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan + Bevacizumab
1st line

Related Medications

Aflibercept
Other Medications
23 trials
Bevacizumab-awwb
Other Medications
1 trials
Cetuximab
Immunotherapy
364 trials
Pembrolizumab
Immunotherapy
196 trials
Panitumumab
Immunotherapy
126 trials
Nivolumab
Immunotherapy
116 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.